Clinical Trials on Myeodysplastic Syndrome

Total 34231 results

Celgene

No longer available

Expanded Access for ACE-011

Myelodysplastic Syndrome

United States
Celgene

Completed

AVIDA The Vidaza® (Azacitidine) Patient Registry (AVIDA)

Myelodysplastic Syndromes

United States
Groupe Francophone des Myelodysplasies
Celgene

Completed

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q (GFM-AZA-REV-09)

Myelodysplastic Syndromes

France
Sanquin Research & Blood Bank Divisions
Netherlands: Ministry of Health, Welfare and Sports

Withdrawn

Transfusion Effects in Myelodysplastic Patients: Limiting Exposure

Myelodysplastic Syndromes

Netherlands
Memorial Sloan Kettering Cancer Center

Completed

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndromes

United States
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
University of Ulm

Terminated

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)
Children's Oncology Group

Completed

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Not yet recruiting

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Relapsed Myelodysplastic Syndrome

United States
University of Leipzig
Curis, Inc.

Terminated

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS)

Myelodysplastic Syndromes | Anemia

Germany
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Myelodysplastic Syndromes

China, Japan
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
Astex Pharmaceuticals, Inc.

Completed

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome | MDS

United States, Canada
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

Myelodysplastic Syndrome | MDS

United States
Mikkael Sekeres MD
National Cancer Institute (NCI)

Completed

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Cedars-Sinai Medical Center
Abbott

Completed

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Alison Walker
Seagen Inc.

Terminated

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Anemia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
European Organisation for Research and Treatment...

Unknown

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Anemia

Belgium, Switzerland, Czech Republic, Portugal, Austria, Netherlands, Slovakia
Case Comprehensive Cancer Center

Completed

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Diseases

United States
National Cancer Institute (NCI)

Completed

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome

United States
University of Leipzig
Celgene Corporation

Recruiting

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions (LENNON)

Myelodysplastic Syndromes | Anemia

Germany
Groupe Francophone des Myelodysplasies
Celgene

Recruiting

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Myelodysplastic Syndromes | MDS

France
Keros Therapeutics, Inc.

Recruiting

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Cytopenia

Australia, Spain, United States, Israel, France, Germany, New Zealand, Czechia
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Anemia

United States
Aprea Therapeutics

Terminated

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | MDS

United States
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

Myelodysplastic Syndromes

Canada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
Eleos, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Terminated

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States
Jonsson Comprehensive Cancer Center
Celgene Corporation; CTI BioPharma

Terminated

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
M.D. Anderson Cancer Center
Novartis

Completed

Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | MDS

United States
ALZA

Unknown

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
University of Arizona

Completed

Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

2 Arm Study of Clofarabine IV in MDS Patients

Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
The Vaccine Company

Terminated

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome

United States
Hadassah Medical Organization

Withdrawn

Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation

Myelodysplastic Syndromes | Myelofibrosis

Israel
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Oxford University Hospitals NHS Trust

Unknown

Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants

Myelodysplastic Syndromes | Leukemia

United Kingdom
Bristol-Myers Squibb

Recruiting

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (ELEMENT-MDS)

Myelodysplastic Syndromes

Canada, United States, China, Australia, France, Greece, Hungary, Germany, Italy, Czechia, Poland, Mexico, Spain, Brazil, Colombia, India, Argentina, Puerto Rico
University Hospital, Bordeaux

Not yet recruiting

Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS) (FerMDS)

Myelodysplastic Syndromes | Ferroptosis

France
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
University of Leipzig
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

Myelodysplastic Syndromes | Anemia

Germany
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Celgene

Completed

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Myelodysplastic Syndromes

Japan

Clinical Trials on Myeodysplastic Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations